Focusing on cancer treatment Halda Therapeutics, $126 million received investment. Total amount of the company’s series B investment round for 202 million dollars reached.
In the investment round of US-based Halda Therapeutics Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital, Taiho Ventures, Canaan Partners, Access Biotechnology, Elm Street Ventures ve Connecticut Innovations took place.
The company announced that it will use the new investment it received to start clinical trials of two new drugs developed for the treatment of prostate and breast cancer.
Halda Therapeutics is defined as a technology company focused on developing innovative solutions for cancer treatment. The company, RIPTA Regulated Induced Proximity Targeting Chimeras He is working on a new cancer treatment method called.
RIPTAC therapies use a trap-and-kill mechanism to target and kill cancer cells. This method aims to overcome the resistance that cancer cells develop against existing drugs. On the one hand, existing cancer drugs may become ineffective due to cells developing resistance. RIPTAC technology aims to provide a more effective treatment by overcoming this resistance.
Halda Therapeutics works on solid tumors that are difficult to treat, such as prostate and breast cancer. These types of cancer are often resistant to standard treatments and can be difficult to treat. The company plans to initiate clinical trials of two main drugs developed with RIPTAC technology.
Source link: https://webrazzi.com/2024/08/13/saglik-girisimi-halda-therapeutics-126-milyon-dolar-yatirim-aldi/